All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Are mini-hyper-CVD combinations adequate for older adults with ALL?
Bookmark this article
During the 8th Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Marlise R. Luskin, Dana-Farber Cancer Institute, Boston, US. We asked, Are mini-hyper-CVD combinations adequate for older adults with ALL?
Are mini-hyper-CVD combinations adequate for older adults with ALL?
In this podcast, Luskin discusses novel agent pairing with mini-hyper-CVD combinations which yield promising results and improved outcomes for older adults with ALL. She comments on studies looking at different treatment regiments with low-dose chemotherapy. For the future, Luskin anticipates another wave of novel agents that will further reduce toxicity and chemotherapy dosage in this patient group.
Your opinion matters
23 votes - 84 days left ...
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox